September 2025 in “Journal of the Pakistan Medical Association” Tofacitinib effectively and safely promotes hair regrowth in alopecia patients.
September 2025 in “Journal of Cosmetic Dermatology” Single-needle radiofrequency is effective and safe for treating facial sebaceous hyperplasia.
September 2025 in “Journal of Dhaka Medical College” Lower vitamin D levels are linked to more severe alopecia areata.
September 2025 in “Journal of the American Academy of Dermatology” Eyebrow and eyelash hair loss in alopecia areata worsens quality of life.
August 2025 in “Lasers in Medical Science” Combining laser therapy with minoxidil improves hair growth and satisfaction without extra side effects.
August 2025 in “International Journal of Women’s Dermatology” Stopping and restarting JAK inhibitors during pregnancy in women with alopecia areata leads to hair loss and regrowth, with most pregnancies resulting in healthy babies.
The KRTAP36-1 gene affects wool quality in Chinese Tan lambs.
July 2025 in “Malaysian Journal of Medicine and Health Sciences” Unmarried individuals and those with diabetes have a poorer quality of life with alopecia areata.
July 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib effectively improves hair regrowth and physician satisfaction in severe alopecia areata over time.
July 2025 in “Journal of Investigative Dermatology” Spironolactone can safely lower blood pressure in patients on other blood pressure medications, but may slightly increase the risk of low blood pressure.
July 2025 in “International Journal of Health and Medicine” Tamsulosin and solifenacin together effectively reduce symptoms in BPH patients.
June 2025 in “Italian Journal of Dermatology and Venereology” Thorough scalp examination is crucial for diagnosing alopecia areata incognita in men with diffuse hair loss.
June 2025 in “International Journal of Science and Research (IJSR)” Low iron and vitamin D are common in young females with hair loss.
May 2025 in “The Journal of Rheumatology” People with lupus find fatigue and skin issues very bothersome, and even small improvements are meaningful.
April 2025 in “Journal of Cosmetic Dermatology” Azathioprine is a safe and effective long-term treatment for severe alopecia areata, significantly improving hair regrowth.
April 2025 in “Dermatology Practical & Conceptual” Increased LC3 gene expression may be linked to premature graying of hair.
April 2025 in “International Journal of Dermatology” JAK inhibitors effectively reduce alopecia areata symptoms in Black patients.
Tofacitinib significantly regrows hair in severe alopecia without major side effects.
April 2025 in “Journal of International Medical Research” Androgenetic alopecia has a minor impact on the quality of life for Jordanian men.
March 2025 in “Pakistan Journal of Health Sciences” Intralesional steroids improve Alopecia Areata, and trichoscopy effectively tracks this improvement.
March 2025 in “Mediterranean Journal of Rheumatology” Laser hair removal is safe for people with Systemic Lupus Erythematosus.
January 2025 in “Dermatologic Surgery” Botulinum toxin injections can safely increase hair count in androgenetic alopecia.
January 2025 in “Orvosi Hetilap” The SASI bypass surgery leads to significant weight loss and improves health conditions with minimal absorption issues.
January 2025 in “Open Science Framework” AA-PRP temporarily increases hair density in androgenetic alopecia but loses effectiveness over time.
January 2025 in “Dermatologic Therapy” Baricitinib effectively promotes hair regrowth in alopecia areata patients with mild side effects.
Human placental extract effectively and safely improves melasma, ulcers, and alopecia areata.
January 2025 in “International Journal of Scientific Research” High serum fluoride levels may be linked to hair loss.
December 2024 in “JEADV Clinical Practice” COVID-19 vaccination is generally safe for people with Hidradenitis Suppurativa.
November 2024 in “Chattagram Maa-O-Shishu Hospital Medical College Journal” Identifying alopecia types early is crucial for better treatment and quality of life.
November 2024 in “Journal of Investigative Dermatology” Tildrakizumab significantly improved psoriasis symptoms and well-being over 52 weeks.